A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer's disease

Gamma-hydroxybutyrate (GHB or Xyrem(R)) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain by therapeutic doses of Xyrem(R) are generally GABAergic-dependent. These e...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's research & therapy 2016-09, Vol.8 (1), p.37-37, Article 37
Main Authors: Maitre, Michel, Klein, Christian, Mensah-Nyagan, Ayikoe G
Format: Article
Language:English
Subjects:
Alzheimer Disease - drug therapy
Alzheimer's disease
Animals
Antidepressants
Cytokines
Dosage and administration
Drug dosages
Drug therapy
FDA approval
Gamma-hydroxybutyrate
Heat shock proteins
Homeostasis
Humans
Life Sciences
Neurobiology
Neurons and Cognition
Neuroprotective Agents - administration & dosage
Pharmaceutical sciences
Pharmacology
Prevention
Rodents
Sleep disorders
Sodium
Sodium Oxybate - administration & dosage
Viewpoint
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gamma-hydroxybutyrate (GHB or Xyrem(R)) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain by therapeutic doses of Xyrem(R) are generally GABAergic-dependent. These effects allow sedation, stress/anxiety reduction, deep sleep induction, decrease of neuroinflammation, and neuroprotection. Furthermore, Xyrem(R) promotes the expression of pivotal genes reducing toxic proteinopathies, as demonstrated in laboratory animal models. Altogether, these data represent additional evidence to suggest that Xyrem(R) may be tested during repeated short periods in populations at risk for Alzheimer's disease.
ISSN:1758-9193
1758-9193
DOI:10.1186/s13195-016-0205-y